Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 11, 2013, Pages 1746-1755

  Xun, Yun hao ^a,b   Zang, Guo qing ^a   Guo, Jian chun ^b   Yu, Xiu li ^b   Liu, Hong ^b   Xiang, Jing ^b   Liu, Jing ^b   Shi, Jun ping ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Chronic HBV carriers; HBeAg positive; Non invasive diagnosis; Quantitative HBsAg; Significant fibrosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; VIRUS CARRIER;

CHRONIC HBV CARRIERS; HBEAG POSITIVE; NON-INVASIVE DIAGNOSIS; QUANTITATIVE HBSAG; SIGNIFICANT FIBROSIS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CARRIER STATE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOM ALLOCATION; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84897602836     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12304     Document Type: Article

References (49)

1. Chan HL, Thompson A, Martinot-Peignoux M etal. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J. Hepatol. 2011; 55: 1121-1131.
2. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 53: 2121-2129.
3. Nguyen T, Thompson AJ, Bowden S etal. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J. Hepatol. 2010; 52: 508-513.
4. Jaroszewicz J, Calle Serrano B, Wursthorn K etal. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J. Hepatol. 2010; 52: 514-522.
5. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-302 e4.
6. Sebastiani G, Castera L, Halfon P etal. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment. Pharmacol. Ther. 2011; 34: 1202-1216.
7. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur. J. Gastroenterol. Hepatol. 2004; 16: 1213-1218.
8. Sanai FM, Helmy A, Bzeizi KI etal. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. J. Viral Hepat. 2011; 18: e217-225.
9. Croagh CM, Bell SJ, Slavin J etal. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int. 2010; 30: 1115-1122.
10. Park H, Lee JM, Seo JH etal. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver Int. 2012; 32: 796-802.
11. Tseng TC, Liu CJ, Yang HC etal. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1193; quiz e13-4.
12. Tseng TC, Liu CJ, Yang HC etal. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57: 441-450.
13. Manesis EK, Papatheodoridis GV, Tiniakos DG etal. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J. Hepatol. 2011; 55: 61-68.
14. Brunetto MR, Oliveri F, Colombatto P etal. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
15. Feld JJ, Heathcote EJ. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin. Liver Dis. 2006; 26: 116-129.
16. Locarnini S, Bowden S. Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology 2012; 56: 411-414.
17. Janssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 2012; 61: 641-645.
18. Jang JW, Yoo SH, Kwon JH etal. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment. Pharmacol. Ther. 2011; 34: 1337-1346.
19. Brunetto MR, Moriconi F, Bonino F etal. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
20. Lee JM, Ahn SH, Kim HS etal. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-1493.
21. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-1257.
22. Rijckborst V, Hansen BE, Ferenci P etal. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J. Hepatol. 2012; 56: 1006-1011.
23. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J. Infect. Dis. 2011; 204: 415-418.
24. Thompson AJ, Nguyen T, Iser D etal. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
25. Wursthorn K, Jung M, Riva A etal. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-1620.
26. Liang Y, Jiang J, Su M etal. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment. Pharmacol. Ther. 2011; 34: 344-352.
27. Chen J, Wang Z, Zhou B, Wang Y, Hou J. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy. Antivir. Ther. 2012; 17: 71-79.
28. Gramenzi A, Loggi E, Micco L etal. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J. Viral Hepat. 2011; 18: e468-474.
29. Kim YJ, Cho HC, Choi MS etal. The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int. 2011; 31: 817-823.
30. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
31. Seto WK, Wong DK, Fung J etal. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS ONE 2012; 7: e43087.
32. Martinot-Peignoux M, Carvalho-Filho R, Lapalus M etal. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J. Hepatol. 2013; 58: 1089-1095.
33. Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin. Med. J. 2007; 120: 2159-2173.
34. Deguchi M, Yamashita N, Kagita M etal. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J. Virol. Methods 2004; 115: 217-222.
35. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
36. Sterling RK, Lissen E, Clumeck N etal. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
37. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 1991; 13: 372-374.
38. Zeng MD, Lu LG, Mao YM etal. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-1445.
39. Rosenberg WM, Voelker M, Thiel R etal. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713.
40. Hui AY, Chan HL, Wong VW etal. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am. J. Gastroenterol. 2005; 100: 616-623.
41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
42. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
43. Zhu X, Wang LC, Chen EQ etal. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig. Dis. Sci. 2011; 56: 2742-2749.
44. Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012; 12: 14.
45. Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J. Gastroenterol. 2010; 16: 501-507.
46. Myers RP, Tainturier MH, Ratziu V etal. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol. 2003; 39: 222-230.
47. Seto WK, Lai CL, Ip PP etal. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS ONE 2012; 7: e32622.
48. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017-1044.
49. Fung J, Lai CL, Young J etal. Stability of hepatitis B surface antigen over time: implications for studies using stored sera. J. Med. Virol. 2011; 83: 1900-1904.